Overview

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

Status:
Completed
Trial end date:
2014-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, safety and tolerability of a single oral dose of [14C] BMS-955176 in healthy male subjects. There is no formal research hypothesis to be statistically tested for this study.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
ViiV Healthcare
Collaborator:
GlaxoSmithKline
Treatments:
BMS-955176